Liver Cancer (Oct 2022)

Tislelizumab in Patients with Previously Treated Advanced Hepatocellular Carcinoma (RATIONALE-208): A Multicenter, Non-Randomized, Open-Label, Phase 2 Trial

  • Zhenggang Ren,
  • Michel Ducreux,
  • Ghassan K. Abou-Alfa,
  • Philippe Merle,
  • Weijia Fang,
  • Julien Edeline,
  • Zhiwei Li,
  • Lihua Wu,
  • Eric Assenat,
  • Sheng Hu,
  • Lorenza Rimassa,
  • Tao Zhang,
  • Jean-Frédéric Blanc,
  • Hongming Pan,
  • Paul Ross,
  • Chia-Jui Yen,
  • Albert Tran,
  • Guoliang Shao,
  • Mohamed Bouattour,
  • Yajin Chen,
  • Tim Meyer,
  • Jinlin Hou,
  • David Tougeron,
  • Yuxian Bai,
  • Ming-Mo Hou,
  • Zhiqiang Meng,
  • John Wu,
  • Vincent Li,
  • Sandra Chica-Duque,
  • Ann-Lii Cheng

DOI
https://doi.org/10.1159/000527175

Abstract

Read online

Introduction: Tislelizumab (anti-programmed cell death protein 1 antibody) showed preliminary antitumor activity and tolerability in patients with advanced solid tumors, including hepatocellular carcinoma (HCC). This study aimed to assess the efficacy and safety of tislelizumab in patients with previously treated advanced HCC. Methods: The multi-regional phase 2 study, RATIONALE-208, examined single-agent tislelizumab (200 mg intravenously every three weeks) in patients with advanced HCC with Child-Pugh A, Barcelona Clinic Liver Cancer stage B or C, and who had received one or more prior lines of systemic therapy. The primary endpoint was objective response rate (ORR), radiologically confirmed per Response Evaluation Criteria in Solid Tumors version 1.1 by Independent Review Committee. Safety was assessed in patients who received ≥1 dose of tislelizumab. Results: Between April 9, 2018 and February 27, 2019, 249 eligible patients were enrolled and treated. After a median study follow-up of 12.7 months, ORR was 13% (n = 32/249; 95% confidence interval [CI], 9–18), including five complete and 27 partial responses. Number of prior lines of therapy did not impact ORR (one prior line, 13% [95% CI, 8–20]; two or more prior lines, 13% [95% CI, 7–20]). Median duration of response was not reached. Disease control rate was 53% and median overall survival was 13.2 months. Of the 249 total patients, grade ≥3 treatment-related adverse events were reported in 38 (15%) patients; the most common was liver transaminase elevations in 10 (4%) patients. Treatment-related adverse events led to treatment discontinuation in 13 (5%) patients or dose delay in 46 (19%) patients. No deaths were attributed to the treatment per investigator assessment. Conclusion: Tislelizumab demonstrated durable objective responses, regardless of the number of prior lines of therapy, and acceptable tolerability in patients with previously treated advanced HCC.